1365267-27-1

Basic information

• Product Name: X-376
• Synonyms: X-376;X-396;6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-3-pyridazinecarboxamide;Ensartinib;(R)-6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-(4-methylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide
• CAS NO: 1365267-27-1
• Molecular Formula: C₂₅H₂₅Cl₂FN₆O₃
• Molecular Weight: 547.4088032
• Mol File: 1365267-27-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 695.1±55.0 °C(Predicted)
• Appearance: /
• Density: 1.428±0.06 g/cm3(Predicted)
• PKA: 10.70±0.70(Predicted)
• CAS DataBase Reference: X-376(CAS DataBase Reference)
• NIST Chemistry Reference: X-376(1365267-27-1)
• EPA Substance Registry System: X-376(1365267-27-1)

Safety Data

• Hazardous Substances Data: 1365267-27-1(Hazardous Substances Data)

Usage

Uses

X-376 is an ALK inhibitor with potential efficacy in the treatment of non-small cell lung cancer.

Side effects

The more common side effects of X-376 treatment include rash, itching, edema, and anemia.

Physiological effects

Ensatinib (X-376) is a second-generation tyrosine kinase inhibitor (TKI) small-molecule targeted drug targeting ALK fusion, which can selectively bind to the products of two driver gene mutations, ALK and MET. Block the activation and transmission of downstream signaling pathways, thereby inhibiting the growth and proliferation of cancer cells with these mutations, and exerting anti-cancer effects.

Upstream product

• 1370651-39-0 C₃₅H₄₁Cl₂FN₆O₇ 
• 1370651-36-7 6-[bis(tert-butoxycarbonyl)amino]-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridazine-3-carboxylic acid 
• 1370651-32-3 C₂₂H₂₅Cl₃FN₃O₅ 
• 1370651-29-8 C₁₂H₉Cl₃FN₃O 
• 330156-50-8 (R)-1-(2,6-dichloro-3-fluorophenyl)ethan-1-ol 
• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 

Relevant articles and documents

SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS

The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against ALK and are useful in treating disorders related to abnormal protein kinase activities such as cancer, neurological and psychiatric diseases